- Home
- CNFR vs NEUP Comparison
CNFR vs NEUP Comparison
Compare CNFR & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNFR
- NEUP
- Stock Information
- Founded
- CNFR 2009
- NEUP 1996
- Country
- CNFR United States
- NEUP United States
- Employees
- CNFR N/A
- NEUP N/A
- Industry
- CNFR Property-Casualty Insurers
- NEUP
- Sector
- CNFR Finance
- NEUP
- Exchange
- CNFR Nasdaq
- NEUP Nasdaq
- Market Cap
- CNFR 7.9M
- NEUP 9.3M
- IPO Year
- CNFR 2015
- NEUP N/A
- Fundamental
- Price
- CNFR $0.82
- NEUP $4.74
- Analyst Decision
- CNFR
- NEUP Strong Buy
- Analyst Count
- CNFR 0
- NEUP 1
- Target Price
- CNFR N/A
- NEUP $21.00
- AVG Volume (30 Days)
- CNFR 35.6K
- NEUP 10.9K
- Earning Date
- CNFR 05-14-2025
- NEUP 05-23-2025
- Dividend Yield
- CNFR N/A
- NEUP N/A
- EPS Growth
- CNFR N/A
- NEUP N/A
- EPS
- CNFR 1.92
- NEUP N/A
- Revenue
- CNFR $66,771,000.00
- NEUP $662,715.00
- Revenue This Year
- CNFR $25.91
- NEUP N/A
- Revenue Next Year
- CNFR N/A
- NEUP N/A
- P/E Ratio
- CNFR $0.43
- NEUP N/A
- Revenue Growth
- CNFR N/A
- NEUP N/A
- 52 Week Low
- CNFR $0.42
- NEUP $2.12
- 52 Week High
- CNFR $1.91
- NEUP $15.24
- Technical
- Relative Strength Index (RSI)
- CNFR 64.23
- NEUP N/A
- Support Level
- CNFR $0.70
- NEUP N/A
- Resistance Level
- CNFR $0.86
- NEUP N/A
- Average True Range (ATR)
- CNFR 0.06
- NEUP 0.00
- MACD
- CNFR 0.02
- NEUP 0.00
- Stochastic Oscillator
- CNFR 83.22
- NEUP 0.00
About CNFR Conifer Holdings Inc.
Conifer Holdings Inc is an insurance holding company. The company markets and services the product offerings of the company through specialty personal insurance business lines. The company offers insurance products in Texas, Illinois, and Indiana for homeowners lines and Nevada and Michigan for other lines. The revenues of the company are derived from premiums earned from insurance operations.
About NEUP Neuphoria Therapeutics Inc. Common Stock
Neuphoria Therapeutics Inc is a clinical stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder.